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ABSTRACT 
 
A steroid is a biologically active organic compound having immunosuppressive action in living organism. 
Different classification of steroids is available in pharmaceutical industry. Steroids are mostly suggested by 
clinician to the patients for the reduction of inflammation caused by immune system. Steroid can cause ele-
vation of patient blood sugar level. Those who take steroids for a longer period of time are more susceptible 
to develop diabetes mellitus. The most commonly used steroids are prednisone and cortisone. These drugs 
promote glucose production in liver and reduce the sensitivity of cells to insulin. In this case report a 45 
year old women suffering from nephrotic syndrome was advised to take Inj. Methyl prednisolone. The ad-
ministration of this drug leads to a rise in her blood sugar level. It is typical case of steroid induced diabetes 
mellitus. 
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INTRODUCTION  
Glucocorticoids are commonly used to treat a wide 
variety of both acute and chronic illnesses. It has pro-
found effects on carbohydrate metabolism: stimulat-
ing liver to form glucose from aminoacids and glyc-
erol. Adverse effects associated with use of steroids 
includes hyperglycaemia and can worsen preexisting 
diabetes or precipitate new “steroid-induced” diabe-
tes, gastritis, glaucoma and hypertension. glucocorti-
coid-induced hyperglycaemia has long been noted in 
humans.[1-5] Steroids elevate blood glucose levels by 
increasing hepatic glucose production and inhibiting 
glucose uptake into muscles. They also have a com-
plex effect on beta cell function.[6-8] The criteria for di-
agnosing diabetes by the American Diabetes Associa-
tion, is an 8 hour fasting blood glucose ≥ 7.0 mmol/L 
(126 mg/dL), 2 hour post 75g oral glucose tolerance 
test (OGTT) ≥ 11.1 mmol/L (200 mg/dL), HbA1c ≥ 
6.5%, or in patients with symptoms of hyperglycemic, 
a random plasma glucose of ≥ 11.1 mmol/L (200 
mg/dL).[9] The effect of glucocorticoids on glucose 
metabolism is likely the result of impairment of mul-
tiple pathways including beta cell dysfunction. risk 
factors for steroid-induced diabetes beyond cumula-
tive dose and longer duration of steroid course in-
clude traditional risk factors for type 2 diabetes- 
older age, family history, high BMI and impaired glu-
cose tolerance.[10] 
CASE REPORT 
A 45 year old women was admitted to a hospital pre-
sented with bilateral lower limb edema from 1 
month, and h/o hematuria, frothy urine. She was di-
agnosed with diabetes mellitus, (blood glucose level 
was 209mg/dl) who had a history of nephrotic syn-
drome, hypertension, hypothyroidism. Patient un-
dergone renal biopsy showed IgA nephropathy with 
2 fibrocellular crescent patient given 3 doses of IV 
methylprednisolone followed by 5 doses of IV cyclo-
phosphamide for every one month and along with 
oral wysolone of 40mg. 
On examination the patient was conscious and coher-
ent and other systemic examinations were BP of 
134/80 mmHg, pulse rate of 90 beats/min, respira-
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tory rate of 22 breaths/min. To treat nephrotic syn-
drome the patient was treated with IV methylpredni-
solone of 3 doses along with oral wysolone of 40mg. 
On adhering to the treatment continuously patient 
suddenly developed raise in blood glucose levels. Sus-
pected to be having steroid induced diabetes mellitus. 
We can understand that the increased blood glucose 
levels was due to prednisolone and the patient was 
treated with metformin of 500mg and then shifted to 
glipizide 5mg and later the dose of prednisolone was 
tapered blood glucose levels stabilized to normal. 
Table 1: Lab Reports 
Lab parameter 
Observed 
value 
Normal value 
Hemoglobin 12.2 g/dl 12-16g/dl 
RBC 
4.7 mil-
lion/cumm 
4.5-5 million/cumm 
WBC 
13300 
cells/cumm 
5000-11000 
cells/cumm 
HbA1c 12.9% 4-6% 
FBS 106 mg/dl 70-110mg/dl 
RBS 127mg/dl 60-140mg/dl 
PPBS 209 mg/dl 160mg/dl 
Serum creati-
nine 
1.41mg/dl 0.30-1.30mg/dl 
Serum potas-
sium 
3.3mmol/L 3.50-5.0mmol/L 
Serum sodium 139mmol/L 135-145mmol/L 
Serum urea 31 mg/dl 10-40 mg/dl 
Serum total 
protein 
7.1g/dl 6-8 g/dl 
 
DISCUSSION  
SIDM is defined as an abnormal increase in blood glu-
cose associated with the use of glucocorticoids in a 
patient with or without a prior history of diabetes 
mellitus.  Steroids are drugs that have been used ex-
tensively in a variety of conditions. Although widely 
prescribed for their anti-inflammatory and immuno-
suppressive properties, glucocorticoids have several 
side effects, being hyperglycemia one of the most 
common and representative.  
Fluctuations in serum glucose levels have been asso-
ciated with increased cardiovascular mortality asso-
ciated with increased LDL cholesterol, endothelial 
dysfunction, activation of the coagulation cascade, in-
creased pro-inflammatory cytokine production, and 
oxidative stress resulting in macrovascular disease 
progression. Several studies have reported that tran-
sient increases in serum glucose are associated with 
acute inflammatory processes and endothelial dys-
function in both diabetic and non-diabetic pa-
tients.[11] There is a need to detect those at risk for de-
veloping steroid-induced diabetes before starting 
chronic therapy. Oral glucose tolerance testing 
(OGTT) should be done as early as possible in pa-
tients who are deemed to be at risk.  
Most patients given glucocorticoids at a dose at least 
equivalent to 40mg/day for more than two days de-
velop hyperglycemia it is well known that glucocorti-
coid therapy may provoke new onset type II diabetes 
mellitus.[12] Initial steps to improve glycemic control 
include lifestyle modification which includes exercise 
and dietary counseling to provide options which can 
perhaps lessen post-prandial hyperglycemia. 
CONCLUSION 
Diabetes is a known complication of steroid therapy 
whether as a single agent or in combination with 
other drugs. The diabetogenic effect of glucocorti-
coids is said to be determined by dose, duration of ad-
ministration and type of steroid. Hence physician has 
to adjust the dose based upon patients pharmacoki-
netic parameters. GCs are drugs that have been 
widely used in a variety of medical conditions. De-
spite their medical efficacy, steroid induced hypergly-
cemia remains as a common potentially harmful 
problem that must be considered when using any 
type a dose of GC. Despite its frequency, little is 
known about the impact of hyperglycemia associated 
with steroid use on clinical co morbidity and mortal-
ity. A proper understanding of the mechanisms in-
volved in steroid hyperglycemia is needed, since this 
will allow early detection and effective treatment in 
these patients. Appropriate guidelines that establish 
the recommendations for the diagnosis and treat-
ment of steroid diabetes are needed in order to pre-
vent all de complications associated with the hyper-
glycemic state. In most cases insulin must be the 
treatment of choice, especially in cases of serum glu-
cose > 200 mg/dl. Nevertheless an individualized ap-
proach must be taken in each patient in order to con-
sider lifestyle modifications and oral hypoglycemic 
drugs as alternative therapeutic 
Cancer describes the disease that result when cellular 
changes cause uncontrolled growth and division of 
cells, the term ‘neoplastic’ a synonym of cancer which 
means ‘new growth’. The meaningful definition of a 
neoplasm or tumour is ‘a mass of tissue formed as a 
result of abnormal, excessive, uncontrolled, autono-
mous and purposeless proliferation of cells even after 
the cessation of the stimulus to growth which caused 
it[1]. In the most basic term, cancer refers to calls that 
grow out of control and invade other tissue. Cells are 
capable of detect and repair DNA damage, if cells is 
severely damaged and cannot repair itself, it usually 
undergoes programmed cell death so called apopto-
sis, cancer occurs when damaged cells grows, divide 
and spread abnormally instead of self-destructing as 
they should.[2]  
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In United States, an estimate of 15.5 million people 
with a history as of Jan 1, 2016, according to the 2018 
report from the American cancer society.[3] There are 
many causes of cancer and over genetics’ most of 
them are preventable. Cancer is the 2nd leading cause 
of death in United States.[4] 
There are many causes of cancer and some of them 
are preventable smoking, heavy alcoholism, obesity, 
physical activity, poor nutrition etc. Genetics influ-
ence the cell production of protein, and proteins that 
carry many of the instruction for cellular growth and 
division. Cancer is more curable when detected early, 
although some cancers develop completely without 
symptoms, or the symptoms are non-specific. Cancer 
treatment advances every year and early detection 
has made many cancers treatable. Cancer symptoms 
and signs are also depend on the size and location of 
the cancer as well as the presence or absence of me-
tastasis.  
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